6 Results

People

  1. Markova
    Markova
  2. Adusumilli
    Adusumilli
  3. Bains
    Bains
  4. Bott
    Bott
  5. Chu
    Chu
  6. D'andrea
    D'andrea
  7. Downey
    Downey
  8. Durney
    Durney
  9. Dycoco
    Dycoco
  10. Glincher
    Glincher

Groups

  1. Survivorship Research (5)
  2. Department of Medicine (4)
  3. Dermatology Service (4)
  4. Dermatology (4)
  5. Division of Subspecialty Medicine (4)
  6. Advanced Practice Providers (1)
  7. Biostatistics Service (1)
  8. Critical Care Center Leadership (1)
  9. Critical Care Center (1)
  10. Epidemiology and Biostatistics (1)
  1. "omalizumab"
Formats
  1. Journal Article (2)
  2. Review (2)
  3. Conference Paper (1)
  4. Editorial (1)
Groups
  1. Survivorship Research (5)
  2. Department of Medicine (4)
  3. Dermatology (4)
  4. Dermatology Service (4)
  5. Division of Subspecialty Medicine (4)
  6. Advanced Practice Providers (1)

More Groups

People
  1. Alina Markova (3)
  2. Mario Lacouture (2)
  3. Angela Lentini-Rivera (1)
  4. Bernard Park (1)
  5. Christina Durney (1)
  6. Christine Kasper (1)

More People

Years
  1. 2025 (1)
  2. 2024 (2)
  3. 2023 (1)
  4. 2021 (1)
  5. 2019 (1)
Publications
  1. Annals of Allergy, Asthma & Immunology (1)
  2. Dermatologic Therapy (1)
  3. Journal of Allergy and Clinical Immunology: In Practice (1)
  4. Journal of Pediatric Hematology/Oncology (1)
  5. Journal of Thoracic and Cardiovascular Surgery (1)
  6. Pharmaceuticals (1)
Publishers
  1. Elsevier B.V. (1)
  2. Elsevier Inc. (1)
  3. Lippincott Williams & Wilkins (1)
  4. MDPI (1)
  5. Mosby Elsevier (1)
  6. Wiley Blackwell (1)

Results (6)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Determinants of successful minimally invasive surgery for resectable non–small cell lung cancer after neoadjuvant therapy
    Conference Paper

    Chu, N. Q.; Tan, K. S.; Dycoco, J.; Adusumilli, P. S.; Bains, M. S.; Bott, M. J.; Downey, R. J.; Gray, K. D.; Huang, J.; Isbell, J. M.; more...
    Mosby Elsevier (2025)

    Fulltext@MSK | Save
  • Omalizumab for treatment of anti-GD2 antibody-related urticaria
    Journal Article

    Glincher, R.; Lentini-Rivera, A.; Jones, L. A.; D'Andrea, L.; Durney, C.; Kasper, C.; Lin, Y.; Shrager, L.; Markova, A.; Lacouture, M.; more...
    Journal of Pediatric Hematology/Oncology (2024)

    Fulltext@MSK | Save
  • Cutaneous hypersensitivity reactions to immune checkpoint inhibitors
    Editorial

    Storgard, R.; Markova, A.
    Journal of Allergy and Clinical Immunology: In Practice (2024)

    Fulltext@MSK | Save
  • Safety of immunomodulatory systemic therapies used in the management of immune-related cutaneous adverse events
    Review

    Gu, S. L.; Nath, S.; Markova, A.
    Pharmaceuticals (2023)

    Fulltext@MSK | Save
  • Immune-related cutaneous adverse events due to checkpoint inhibitors
    Review

    Wang, E.; Kraehenbuehl, L.; Ketosugbo, K.; Kern, J. A.; Lacouture, M. E.; Leung, D. Y. M.
    Annals of Allergy, Asthma & Immunology (2021)

    Fulltext@MSK | Save
  • The efficacy of omalizumab in cutaneous mastocytosis: A case series
    Journal Article

    Hinojosa, T.; Lewis, D. J.; Vangipuram, R.; Safeer, L.; Mui, U. N.; Haley, C.; Konoplev, S.; Tyring, S. K.
    Dermatologic Therapy (2019)

    Fulltext@MSK | Save